Table 5.
Univariate analysis of re-bleeding related factors
| Variables, n (%) | Re-bleeding within 12 months after discharge | OR (95% CI) | P-value | |
|---|---|---|---|---|
| Yes (n = 28) | No (n = 38) | |||
| Age> 65 years | 13 (46.43) | 10 (26.32) | 2.427 (0.861–6.837) | 0.090 |
| Male sex | 10 (35.71) | 21 (55.26) | 0.450 (0.165–1.226) | 0.116 |
| History of smoking | 4 (16.29) | 11 (28.95) | 0.409 (0.115–1.456) | 0.160 |
| History of drinking | 2 (7.14) | 6 (15.79) | 0.410 (0.076–2.205) | 0.495 |
| Drug use of antithrombotic | 4 (14.29) | 4 (10.53) | 1.417 (0.322–6.230) | 0.935 |
| Personal history of malignancy | 2 (7.14) | 3 (7.89) | 0.897 (0.140–5.763) | > 0.999 |
| History of gastrointestinal surgery | 2 (7.14) | 4 (10.53) | 0.654 (0.111–3.348) | 0.969 |
| RBC transfusion before admission | 24 (85.71) | 19 (50.00) | 6.000 (1.745–20.627) | 0.003* |
| Hypertension | 19 (67.86) | 23 (60.53) | 1.377 (0.494–3.840) | 0.541 |
| Liver cirrhosis | 4 (14.29) | 4 (10.53) | 1.417 (0.322–6.230) | 0.935 |
| With type 1b lesions | 23 (82.14) | 25 (65.79) | 2.392 (0.737–7.758) | 0.140 |
| Most lesions in jejunum | 1 (3.57) | 6 (15.79) | 0.197 (0.022–1.744) | 0.234 |
| Multiple lesions (≥ 3) | 25 (89.29) | 24 (63.16) | 4.861 (1.239–19.072) | 0.016* |
| Lesions with active oozing/bleeding | 2 (7.14) | 5 (13.16) | 0.508 (0.091–2.831) | 0.704 |
| HB ≤ 70 g/L | 15 (53.57) | 10 (26.32) | 3.231 (1.147–9.102) | 0.024* |
| PLT <125 10^9 | 7 (25.00) | 9 (23.68) | 1.074 (0.345–3.346) | 0.902 |
| ALB< 35 g/L | 11 (39.29) | 14 (36.84) | 1.109 (0.406–3.030) | 0.840 |
| EIS treatment | 7 (25.00) | 24 (63.16) | 0.194 (0.066–0.572) | 0.002* |
NOTE: We did not assess PT, APTT and TBIL because the number of patients with abnormal detection value (PT> 13.0 s, APTT> 40.0 s, or TBIL> 20.4 umol/L) < 5 in the total cohort; for the same reason, cardiovascular disease, chronic renal failure and diabetes were not involved in the univariate analysis. *: P < 0.05 was considered of significant difference
Abbreviations: OR, odds ratio; CI, confidence interval; RBC, red blood cell; HB, hemoglobin; PLT, blood platelet; PT, prothrombin time; APTT, activated partial thromboplastin time; TBIL, total bilirubin; ALB, serum albumin; EIS, endoscopic injection sclerotherapy